- Predictive
Oncology subsidiary TumorGenesis developing faster, less costly and more
accurate PDx cancer models that better mimic patient’s tumor
- TumorGenesis
revolutionary technology will provide pharmaceuticals with quicker, more
effective drug development while significantly improving patient outcomes
- POAI
to begin sales of TumorGenesis’ innovative culture media in the first half
of 2020
TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete
steps in identifying and separating cancer-related biomarkers, which is likely
to speed the development of new and effective therapeutics. TumorGenesis media
are specially formulated to help researchers isolate and maintain the unique
histological and basic biological signatures of ovarian cell types while
growing them in the laboratory. This breakthrough approach is likely to help
POAI become a frontrunner in providing the needed tools for personalized
medicine and new drug development, which carries important implications for the
company’s future valuation.
For years, clinicians believed that isolating a patient’s
tumor would lead to new understandings about the cancer – this has proven to be
only partly true and has resulted in costly, ineffective drug diagnoses that
have robbed patients of precious time. To substantially enhance the
effectiveness of cancer treatment, a much more diverse picture of patient
tumors is needed – one that takes into account each individual’s unique
biodiversity and the unique biodiversity of each tumor. POAI’s TumorGenesis
division is at the forefront of a whole new trend in cancer research that
revolves around patient derived xenografts (PDx).
Science has shifted to these much more accurate PDx models:
A cancer patient’s tumor cells are implanted into an alternate environment to
simulate the natural development of the tumor. By “fooling the tumor” with an
imitative environment, new drugs are able to be tested and potentially approved
– all without subjecting cancer patients to aggressive, potentially ineffective
drugs. The cancer cells are tricked into thinking they’re still multiplying
inside the patient, which makes the tumor behave as it would normally – revealing
more precise cancer biomarkers. TumorGenesis’ unique research approach benefits
from the parent company’s enormous database of tumor drug response profiles and
artificial intelligence-driven predictive modeling capabilities.
TumorGenesis has developed its proprietary methodology using
PDx to culture tumor cells in vivo, (i.e. in living organisms). These cell
models can be then tested repeatedly for various new drugs to establish
personalized therapeutics. This patient-specific data is revolutionizing the
way cancer is treated today, and POAI, through its strategic subsidiary arms,
poses an attractive option for investors looking to invest in the cancer
treatment of tomorrow.
In light of the traditional past practice of studying how
cancer cell lines react to induced mutation (a practice that has since proven
to be seriously flawed), cancer researchers are shifting their focus to PDx
techniques, which have grown into a multibillion-dollar industry. TumorGenesis
is poised to become a dominant figure in this emerging space. US Biological
Corporation of Salem, Massachusetts has been selected as the distributor of
TumorGenesis media and discovery kits.
Parent company POAI already presents a major leap in the
cancer research industry. As of today, the company has validated and will begin
sales its new PDx models for ovarian cancer (http://ibn.fm/1hsgV) in the first half of this year. The
company now has 25 validated ovarian cancer cell types. This signifies
remarkable comprehension of the notoriously difficult-to-detect cancer, as 15
out of the 25 cell lines account for nine out of ten ovarian cancers diagnosed
worldwide. As researchers separate these types and analyze their reaction to
drug samples, POAI’s findings could greatly improve future patient outcomes.
In line with its CancerQuest2020 initiative, ovarian cancer
is just POAI’s first target. With monetization, the company plans to diversify
and expand its catalogue of validated cancers; future plans include thyroid,
breast, colon, and prostate cancers, among others.
TumorGenesis presents POAI with multiple revenue streams.
Based on its unique PDx samples, the company is testing drugs individually and
holistically against its massive library of ovarian cancer cell types. Using
this approach, the company is building kits for cancer research laboratories
worldwide. The company is also committed to immunological research. Its
proprietary Ovarian Cancer Kit can help simulate a patient’s cancer
environment, and these new tools can be used to help isolate various strains of
the complex tumor environment that to this date, have never been isolated but
seen by genetic and proteomic analysis. Once isolated, these subtypes of tumor
cells can be studied, new antibodies developed and new tools researched for
killing not just the fast growing tumor variants but also the entire tumor.
The latest developments in TumorGenesis’ PDx efforts could
secure a significant segment of the cancer research industry. TumorGenesis’
advances in ovarian cancer models provides POAI a unique competitive advantage
that could easily be converted into rapid market expansion. This expansion
would not only further validate efficacy and grow market share, it would likely
lead to significant increase in POAI’s market valuation. As the company
continues achieving milestones of its CancerQuest2020, POAI is setting up to
become one of the biotech superstars of 2020 and beyond.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
